Gilles Montalescot, ESC 2019 – the ADRIFT Study
We spoke to Professor Gilles Montalescot (ACTION study group, Pitie-Salpetriere Hospital, Paris, France) about the results from the ADRIFT study, evaluating the use of two doses of rivaroxaban compared to dual antiplatelet therapy in patients with atrial fibrillation after left atrial appendage closure, and how physicians might use these findings in the management of their patients.
Speaker’s Disclosures: Gilles Montalescot has received research funds for ActionCoeur or fees from Abbott, Amgen, Actelion, American College of Cardiology Foundation, AstraZeneca, Axis-Health, Bayer, Boston Scientific, Boehringer Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, China Heart House, Daiichi-Sankyo, Idorsia, Elsevier, Europa, French Federation of Cardiology, ICAN, Lead-Up, Medtronic, Menarini, MSD, Novo-Nordisk, Partners, Pfizer, Quantum Genomics, Sanofi, Servier and WebMD.
1. What were the aims and key findings of the ADRIFT study? (0:04)
2. Where there any notable differences between the two regimens of high (15 mg) or low (10 mg) dose rivaroxaban? (2:09)
3. How should physicians consider these findings in the management of their patients following left atrial appendage closure? (2:51)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with the Arrhythmia Alliance (A-A) at the European Society of Cardiology (ESC) Congress 2019 in Paris, France, September 2019.
Share this Video
Related Videos In Atrial Fibrillation
Bruce Wilkoff, EHRA 2023: The AdaptResponse trial, synchronized left ventricular pacing for heart failure with left bundle branch block
The AdaptResponse trial was designed to assess two methods of restoring resynchronization to the heart in patients with heart failure with left bundle branch block. In this touchCARDIO interview, we speak with Dr Bruce Wilkoff (Cleveland Clinic, Cleveland, OH, USA) to discuss the design of the AdaptResponse trial, the outcomes as well as the clinical […]
Bruce Wilkoff, EHRA 2023: An overview of cardiac resynchronization therapy for patients with heart failure
Cardiac resynchronization therapy is designed to restore the electrical activation in a more natural way in patients with heart failure. In this touchCARDIO interview, we speak with Dr Bruce Wilkoff (Cleveland Clinic, Cleveland, OH, USA) to discuss the treatment paradigm with focus on cardiac resynchronization therapy for patients with heart failure. Bruce Wilkoff presented an […]
Søren Zöga Diederichsen, EHRA 2023: NT-proBNP as a tool for atrial fibrillation screening, post hoc analysis of the LOOP study
Recently it has been shown that NT-proBNP may be a useful tool for finding people with an increased risk of atrial fibrillation and stroke. In this touchCARDIO interview, we speak with Dr Søren Zöga Diederichsen (Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark) to discuss the post hoc analysis of the LOOP study. The abstract entitled ‘Atrial […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!